孕前糖尿病与妊娠:内分泌学会与欧洲内分泌学会联合临床实践指南
该指南由内分泌学会与欧洲内分泌学会联合制定,针对孕前糖尿病(PDM)患者在孕前、孕期及产后的管理提出10个临床问题的推荐。推荐涵盖妊娠意向筛查、避孕、GLP-1RA停用时机、二甲双胍使用、饮食、血糖监测、闭环泵、分娩时机及产后内分泌照护,证据确定性为极低至低。
要点
- 对可能妊娠的糖尿病患者,每次就诊时建议(弱推荐)询问妊娠意向。
- 2型糖尿病患者建议(弱推荐)孕前停用GLP-1受体激动剂而非孕早期停用。
- 使用持续葡萄糖监测者,建议不(弱推荐)采用单一24小时目标<140 mg/dL替代标准孕期血糖目标。
核心结论
- 支持这些推荐的数据确定性为极低至低,突出亟需设计研究以提供高确定性证据。
- 投资实施科学以预防孕前糖尿病患者及其子女的重大死亡和疾病至关重要。
- 需要随机对照试验进一步明确孕期血糖目标并完善新兴技术以达到这些目标。
- 孕期最佳营养和肥胖管理的数据缺乏,需要更多关于孕前糖尿病患者分娩时机的研究。
研究设计与样本
- 指南制定小组由多学科临床专家及指南方法学和系统文献综述专家组成,确定并优先处理10个与糖尿病孕前、孕期及产后照护相关的临床问题。
- 优先评估随机对照试验(RCT),系统综述检索电子数据库,采用GRADE方法评估证据确定性并制定推荐。
- 方法纳入2名患者代表观点,考虑患者价值观、成本资源、可接受性可行性及健康公平性影响。
主要发现
- 孕前照护(PCC)与降低首次产前检查糖化血红蛋白(HbA1c)及先天畸形强烈相关(间接证据)。
- 对RCT的Meta分析显示,使用混合闭环泵技术改善血糖指标:范围内时间增加(MD +3.81%;CI -4.24至11.86),低于范围时间减少(MD -0.85%;CI -1.98至0.28)。
- 关于GLP-1受体激动剂孕期暴露风险的数据有限。
- 指南制定小组判断,在胰岛素基础上加用二甲双胍以降低大于胎龄儿发生率的获益,不超过增加小于胎龄儿或儿童期体成分变化相关不良结局风险的潜在危害。
- 关于碳水化合物限制饮食(<175 g/天)与常规饮食(>175 g/天)的现有证据有限且非常间接,对净获益或危害存在显著不确定性。
关键数值与推荐
- 对可能妊娠的糖尿病患者,建议(弱推荐)每次生殖、糖尿病和初级保健就诊时询问妊娠意向;在临床适当时急诊就诊也建议筛查(2 | ⊕OOO)。
- 对可能妊娠的糖尿病患者,当不期望妊娠时建议(弱推荐)使用避孕(2 | ⊕⊕OO)。
- 对2型糖尿病患者,建议(弱推荐)孕前停用GLP-1受体激动剂,而非在妊娠开始至孕早期结束之间停用(2 | ⊕OOO)。
- 对已使用胰岛素的2型糖尿病孕妇,建议不(弱推荐)常规加用二甲双胍(2 | ⊕OOO)。
- 对孕前糖尿病患者,建议(弱推荐)孕期采用碳水化合物限制饮食(<175 g/天)或常规饮食(>175 g/天)中的任一种(2 | ⊕OOO)。
临床怎么用
- 对可能妊娠的糖尿病患者,每次就诊时询问妊娠意向并筛查。
- 不期望妊娠时建议使用避孕。
- 2型糖尿病患者孕前停用GLP-1受体激动剂。
- 使用CGM者不采用单一24小时目标<140 mg/dL替代标准孕期血糖目标。
- 1型糖尿病孕妇建议使用混合闭环泵。
局限性
- 支持这些推荐的数据确定性为极低至低。
- 关于GLP-1受体激动剂孕期暴露风险的数据有限。
- 关于碳水化合物限制饮食与常规饮食的证据有限且非常间接,对净获益或危害存在显著不确定性。
- 缺乏直接证据支持CGM优于SMBG用于2型糖尿病孕期。
- 孕期最佳营养和肥胖管理的数据缺乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preexisting diabetes (PDM) increases the risk of maternal and perinatal mortality and morbidity. Reduction of maternal hyperglycemia prior to and during pregnancy can reduce these risks. Despite compelling evidence that preconception care (PCC), which includes achieving strict glycemic goals, reduces the risk of congenital malformations and other adverse pregnancy outcomes, only a minority of individuals receive PCC. Suboptimal pregnancy outcomes demonstrated in real-world data highlight the need to further optimize prenatal glycemia. New evolving technology shows promise in helping to achieve that goal. Dysglycemia is not the only driver of poor pregnancy outcomes in PDM. The increasing impact of obesity on pregnancy outcomes underscores the importance of optimal nutrition and management of insulin sensitizing medications during prenatal care for PDM. OBJECTIVE: To provide recommendations for the care of individuals with PDM that lead to a reduction in maternal and neonatal adverse outcomes. METHODS: The Guideline Development Panel (GDP) composed of a multidisciplinary panel of clinical experts, along with experts in guideline methodology and systematic literature review, identified and prioritized 10 clinically relevant questions related to the care of individuals with diabetes before, during and after pregnancy. The GDP prioritized randomized controlled trials (RCTs) evaluating the effects of different interventions (eg, PCC, nutrition, treatment options, delivery) during the reproductive life cycle of individuals with diabetes, including type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Systematic reviews queried electronic databases for publications related to these 10 clinical questions. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology was used to assess the certainty of evidence and develop recommendations. The approach incorporated perspectives from 2 patient representatives and considered patient values, costs and resources required, acceptability and feasibility, and impact on health equity of the proposed recommendations. RESULTS: In individuals with diabetes mellitus who have the possibility of becoming pregnant, we suggest asking a screening question about pregnancy intention at every reproductive, diabetes, and primary care visit. Screening for pregnancy intent is also suggested at urgent care/emergency room visits when clinically appropriate (2 | ⊕OOO). This was suggested based on indirect evidence demonstrating a strong association between PCC and both reduced glycated hemoglobin (HbA1c) at the first prenatal visit and congenital malformations.In individuals with diabetes mellitus who have the possibility of becoming pregnant, we suggest use of contraception when pregnancy is not desired (2 | ⊕⊕OO). This was suggested based on indirect evidence in women with diabetes, where PCC-including contraception as a key component-showed a clinically significant association with improvements in first-trimester HbA1c and the rate of congenital malformations, together with indirect evidence from the general population regarding the reduction of unplanned pregnancies and pregnancy terminations with the use of contraception.In individuals with T2DM, we suggest discontinuation of glucagon-like peptide-1 receptor agonist (GLP-1RA) before conception rather than discontinuation between the start of pregnancy and the end of the first trimester (2 | ⊕OOO). This was suggested based on limited data on risk of exposure to GLP-1RA receptor agonists during pregnancy.In pregnant individuals with T2DM already on insulin, we suggest against routine addition of metformin (2 | ⊕OOO). This was suggested based on the GDP judgment that the benefit of adding metformin to insulin to achieve decrease in rates of large for gestational age infants did not outweigh the potential harm of increasing the risk of small for gestational age infants or adverse childhood outcomes related to changes in body composition.In individuals with PDM, we suggest either a carbohydrate-restricted diet (<175 g/day) or usual diet (>175 g/day) during pregnancy (2 | ⊕OOO). This was suggested based on the GDP judgment that the available evidence was limited and very indirect, resulting in significant uncertainty about the net benefits or harms. As such, the evidence was insufficient to support a recommendation either for or against a carbohydrate intake cutoff of 175 g/day.In pregnant individuals with T2DM, we suggest either the use of a continuous glucose monitor (CGM) or self-monitoring of blood glucose (SMBG) (2 | ⊕OOO). There is lack of direct evidence supporting superiority of CGM use over SMBG for T2DM during pregnancy. There is indirect evidence supporting improved glucometrics with the use of CGM for individuals with T2DM outside of pregnancy, substantial improvements in neonatal outcomes for individuals with T1DM using CGM during pregnancy and the potential for decreasing adverse pregnancy outcomes with improved glucometrics in individuals with T2DM.In individuals with PDM using a CGM, we suggest against the use of a single 24-hour CGM target <140 mg/dL (7.8 mmol/L) in place of standard-of-care pregnancy glucose targets of fasting <95 mg/dL (5.3 mmol/L), 1-hour postprandial <140 mg/dL (7.8 mmol/L), and 2-hour postprandial < 120 mg/dL (6.7 mmol/L) (2 | ⊕OOO). This was suggested based on indirect evidence that associated adverse pregnancy outcomes with a fasting glucose > 126 mg/dL (7 mmol/L).In individuals with T1DM who are pregnant, we suggest the use of a hybrid closed-loop pump (pump adjusting automatically based on CGM) rather than an insulin pump with CGM (without an algorithm) or multiple daily insulin injections with CGM (2 | ⊕OOO). This was suggested based on a meta-analysis of RCTs which demonstrated improvement in glucometrics with increased time in range (MD +3.81%; CI -4.24 to 11.86) and reduced time below range (MD -0.85%; CI -1.98 to 0.28) with the use of hybrid closed-loop pump technology.In individuals with PDM, we suggest early delivery based on risk assessment rather than expectant management (2 | ⊕OOO). This was suggested based on indirect evidence that risks may outweigh benefits of expectant management beyond 38 weeks gestation and that risk assessment criteria may be useful to inform ideal delivery timing.In individuals with PDM (including those with pregnancy loss or termination), we suggest postpartum endocrine care (diabetes management), in addition to usual obstetric care (2 | ⊕OOO). As the postpartum period frequently overlaps with preconception, this was suggested based on indirect evidence demonstrating a strong association between PCC and both reduced HbA1c at the first prenatal visit and congenital malformations. CONCLUSION: The data supporting these recommendations were of very low to low certainty, highlighting the urgent need for research designed to provide high certainty evidence to support the care of individuals with diabetes before, during, and after pregnancy. Investment in implementation science for PCC is crucial to prevent significant mortality and morbidity for individuals with PDM and their children. RCTs to further define glycemic targets in pregnancy and refinement of emerging technology to achieve those targets can lead to significant reduction of harm and in the burden of diabetes care. Data on optimal nutrition and obesity management in pregnancy are lacking. More research on timing of delivery in women with PDM is also needed.
引用
- Wyckoff JA, Lapolla A, Asias-Dinh BD, et al. Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline. J Clin Endocrinol Metab. 2025. PMID: 40652453. doi:10.1210/clinem/dgaf288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。